Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.

Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G.

Int J Radiat Oncol Biol Phys. 2019 May 11. pii: S0360-3016(19)30698-4. doi: 10.1016/j.ijrobp.2019.04.034. [Epub ahead of print]

PMID:
31082494
2.

Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features.

Schoenfeld JD, Nishino M, Severgnini M, Manos M, Mak RH, Hodi FS.

J Immunother Cancer. 2019 Apr 24;7(1):112. doi: 10.1186/s40425-019-0583-3.

3.

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.

Fareed MM, Pike LRG, Bang A, Huynh MA, Taylor A, Spektor A, Awad MM, Ott PA, Krishnan M, Balboni TA, Schoenfeld JD.

Front Oncol. 2019 Mar 29;9:199. doi: 10.3389/fonc.2019.00199. eCollection 2019.

4.

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.

Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS, Schoenfeld JD, Ott PA.

J Immunother Cancer. 2019 Mar 29;7(1):89. doi: 10.1186/s40425-019-0512-5.

5.

Radiation Therapy and Immune Modulation.

Leeman JE, Schoenfeld JD.

Hematol Oncol Clin North Am. 2019 Apr;33(2):233-248. doi: 10.1016/j.hoc.2018.12.003. Epub 2019 Jan 17. Review.

PMID:
30832997
6.

Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence.

Arbab M, Margalit DN, Tishler RB, Rabinowits G, Pashtan IM, Borgelt BB, Powlis W, Holdsworth CH, Warren LE, Schoenfeld JD.

Head Neck. 2019 Jul;41(7):2111-2115. doi: 10.1002/hed.25663. Epub 2019 Jan 29.

PMID:
30697925
7.

IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing.

LaVigne AW, Margalit DN, Rawal B, Puzanov M, Annino DJ, Goguen LA, Sher DJ, Schoenfeld JD, Chau NG, Lorch JH, Rabinowits G, Haddad RI, Tishler RB.

Head Neck. 2019 Apr;41(4):959-966. doi: 10.1002/hed.25531. Epub 2019 Jan 8.

PMID:
30620435
8.

Pharmacological Ascorbate as a Means of Sensitizing Cancer Cells to Radio-Chemotherapy While Protecting Normal Tissue.

Schoenfeld JD, Alexander MS, Waldron TJ, Sibenaller ZA, Spitz DR, Buettner GR, Allen BG, Cullen JJ.

Semin Radiat Oncol. 2019 Jan;29(1):25-32. doi: 10.1016/j.semradonc.2018.10.006. Review.

PMID:
30573181
9.

We Are All Connected: Modeling the Tumor-Immune Ecosystem.

Schoenfeld JD.

Trends Cancer. 2018 Oct;4(10):655-657. doi: 10.1016/j.trecan.2018.08.006. Epub 2018 Sep 13.

PMID:
30292347
10.

Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies.

Fitarelli-Kiehl M, Yu F, Ashtaputre R, Leong KW, Ladas I, Supplee J, Paweletz C, Mitra D, Schoenfeld JD, Parangi S, Makrigiorgos GM.

Clin Chem. 2018 Dec;64(12):1762-1771. doi: 10.1373/clinchem.2018.293845. Epub 2018 Oct 1.

11.

The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors.

Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, Cagney DN, Aizer AA, Alexander BM, Rahma O, Balboni T, Ott PA, Hodi FS, Schoenfeld JD.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151. doi: 10.1016/j.ijrobp.2018.09.010. Epub 2018 Sep 15.

PMID:
30227198
12.

Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.

Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD.

Oral Oncol. 2018 Oct;85:29-34. doi: 10.1016/j.oraloncology.2018.08.005. Epub 2018 Aug 17.

PMID:
30220316
13.

Immunotherapy and radiotherapy for metastatic cancers.

Bang A, Schoenfeld JD.

Ann Palliat Med. 2018 Aug 22. pii: apm.2018.07.10. doi: 10.21037/apm.2018.07.10. [Epub ahead of print]

14.

Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy.

Giacalone NJ, Milani N, Rawal B, Catalano PJ, Nguyen PL, Schoenfeld JD, Tishler RB, Margalit DN.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):34-43. doi: 10.1016/j.ijrobp.2018.05.037. Epub 2018 May 22.

PMID:
29970311
15.

Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.

Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):137-145. doi: 10.1016/j.ijrobp.2018.05.002. Epub 2018 Jun 29.

PMID:
29960819
16.

Corrigendum to: Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells [Redox Biol. (2018) 82-87].

Brandt KE, Falls KC, Schoenfeld JD, Rodman SN 3rd, Gu Z, Zhan F, Cullen JJ, Wagner BA, Buettner GR, Allen BG, Berg DJ, Spitz DR, Fath MA.

Redox Biol. 2018 Jun 8. pii: S2213-2317(18)30481-6. doi: 10.1016/j.redox.2018.06.001. [Epub ahead of print] No abstract available.

17.

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

McGee HM, Daly ME, Azghadi S, Stewart SL, Oesterich L, Schlom J, Donahue R, Schoenfeld JD, Chen Q, Rao S, Fragoso RC, Valicenti RK, Canter RJ, Maverakis EM, Murphy WJ, Kelly K, Monjazeb AM.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1259-1270. doi: 10.1016/j.ijrobp.2018.04.038. Epub 2018 Apr 22.

PMID:
29891204
18.

Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy.

Walker R, Schoenfeld JD, Pilon-Thomas S, Poleszczuk J, Enderling H.

Converg Sci Phys Oncol. 2017 Sep;3(3). pii: 034001. doi: 10.1088/2057-1739/aa7269. Epub 2017 Jun 15.

19.

Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy.

Alexander BM, Schoenfeld JD, Trippa L.

N Engl J Med. 2018 Mar 22;378(12):1158-1159. doi: 10.1056/NEJMc1716612. No abstract available.

PMID:
29562148
20.

Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI.

JCI Insight. 2018 Feb 22;3(4). pii: 98811. doi: 10.1172/jci.insight.98811. eCollection 2018 Feb 22.

21.

Using immunotherapy to boost the abscopal effect.

Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC.

Nat Rev Cancer. 2018 May;18(5):313-322. doi: 10.1038/nrc.2018.6. Epub 2018 Feb 16. Review.

22.

Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation.

Martin AM, Cagney DN, Catalano PJ, Alexander BM, Redig AJ, Schoenfeld JD, Aizer AA.

JAMA Oncol. 2018 Aug 1;4(8):1123-1124. doi: 10.1001/jamaoncol.2017.3993. No abstract available.

23.

The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline.

Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H.

Oncologist. 2017 Nov;22(11):1413. doi: 10.1634/theoncologist.2016-0298erratum. No abstract available.

24.

Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Bradley MD, Wagner BA, Buettner GR, Monga V, Milhem M, Spitz DR, Allen BG.

Redox Biol. 2018 Apr;14:417-422. doi: 10.1016/j.redox.2017.09.012. Epub 2017 Sep 28.

25.

Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy.

Margalit DN, Schoenfeld JD, Rawal B, Haddad RI, Catalano PJ, Goguen LA, Chau NG, Rabinowits G, Lorch JH, Annino DJ, Tishler RB.

Oral Oncol. 2017 Oct;73:160-165. doi: 10.1016/j.oraloncology.2017.08.012. Epub 2017 Sep 8.

PMID:
28939070
26.

Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer.

Rabinowits G, Bowden M, Flores LM, Verselis S, Vergara V, Jo VY, Chau N, Lorch J, Hammerman PS, Thomas T, Goguen LA, Annino D, Schoenfeld JD, Margalit DN, Tishler RB, Haddad RI.

Front Oncol. 2017 Aug 29;7:191. doi: 10.3389/fonc.2017.00191. eCollection 2017.

27.

Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells.

Brandt KE, Falls KC, Schoenfeld JD, Rodman SN, Gu Z, Zhan F, Cullen JJ, Wagner BA, Buettner GR, Allen BG, Berg DJ, Spitz DR, Fath MA.

Redox Biol. 2018 Apr;14:82-87. doi: 10.1016/j.redox.2017.08.017. Epub 2017 Aug 26. Erratum in: Redox Biol. 2018 Jun 8;:.

28.

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Kauffman EPS, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG.

Cancer Cell. 2017 Aug 14;32(2):268. doi: 10.1016/j.ccell.2017.07.008. No abstract available.

29.

Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy.

Mapuskar KA, Flippo KH, Schoenfeld JD, Riley DP, Strack S, Hejleh TA, Furqan M, Monga V, Domann FE, Buatti JM, Goswami PC, Spitz DR, Allen BG.

Cancer Res. 2017 Sep 15;77(18):5054-5067. doi: 10.1158/0008-5472.CAN-17-0106. Epub 2017 Aug 1.

30.

Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation.

Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD.

Radiother Oncol. 2017 Jul;124(1):98-103. doi: 10.1016/j.radonc.2017.06.006. Epub 2017 Jun 26.

PMID:
28662869
31.

Prospective analysis of radiation oncology image and plan-driven peer review for head and neck cancer.

Zairis S, Margalit DN, Royce TJ, Powlis WD, Tishler RB, Schoenfeld JD.

Head Neck. 2017 Aug;39(8):1603-1608. doi: 10.1002/hed.24800. Epub 2017 May 17.

PMID:
28513902
32.

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.

Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA, Hodi FS, Schoenfeld JD.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):344-351. doi: 10.1016/j.ijrobp.2017.02.003. Epub 2017 Feb 11.

PMID:
28463153
33.

D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress.

Sciegienka SJ, Solst SR, Falls KC, Schoenfeld JD, Klinger AR, Ross NL, Rodman SN, Spitz DR, Fath MA.

Free Radic Biol Med. 2017 Jul;108:354-361. doi: 10.1016/j.freeradbiomed.2017.04.001. Epub 2017 Apr 5.

34.

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.

Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD.

Cancer Biomark. 2017;19(2):129-136. doi: 10.3233/CBM-160071.

PMID:
28387659
35.

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG.

Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268.

36.

Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.

Hanna GJ, Liu H, Jones RE, Bacay AF, Lizotte PH, Ivanova EV, Bittinger MA, Cavanaugh ME, Rode AJ, Schoenfeld JD, Chau NG, Haddad RI, Lorch JH, Wong KK, Uppaluri R, Hammerman PS.

Oral Oncol. 2017 Apr;67:61-69. doi: 10.1016/j.oraloncology.2017.02.005. Epub 2017 Feb 14.

PMID:
28351582
37.

The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline.

Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H.

Oncologist. 2017 Mar;22(3):343-350. doi: 10.1634/theoncologist.2016-0298. Epub 2017 Feb 16. Review. Erratum in: Oncologist. 2017 Nov;22(11):1413.

38.

Merkel Cell Carcinoma: A Population Analysis on Survival.

Sridharan V, Muralidhar V, Margalit DN, Tishler RB, DeCaprio JA, Thakuria M, Rabinowits G, Schoenfeld JD.

J Natl Compr Canc Netw. 2016 Oct;14(10):1247-1257.

PMID:
27697979
39.

Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences.

Margalit DN, Rawal B, Catalano PJ, Haddad RI, Goguen LA, Annino DJ, Limaye SA, Lorch JH, Lavigne AW, Schoenfeld JD, Sher DJ, Tishler RB.

Oral Oncol. 2016 Oct;61:19-26. doi: 10.1016/j.oraloncology.2016.07.012. Epub 2016 Aug 6.

PMID:
27688100
40.

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD.

Br J Cancer. 2016 Jul 12;115(2):252-60. doi: 10.1038/bjc.2016.166. Epub 2016 Jul 5.

41.

Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD.

J Immunother Cancer. 2016 Jun 21;4:32. doi: 10.1186/s40425-016-0138-9. eCollection 2016.

42.

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.

Sridharan V, Gjini E, Liao X, Chau NG, Haddad RI, Severgnini M, Hammerman P, El-Naggar A, Freeman GJ, Hodi FS, Rodig SJ, Dranoff G, Schoenfeld JD.

Cancer Immunol Res. 2016 Aug;4(8):679-87. doi: 10.1158/2326-6066.CIR-16-0031. Epub 2016 Jun 16.

43.

Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer.

Keane FK, Chen YH, Tishler RB, Schoenfeld JD, Haddad RI, Goguen LA, Catalano P, Neville BA, Margalit DN.

Head Neck. 2016 Oct;38(10):1530-8. doi: 10.1002/hed.24470. Epub 2016 Apr 15.

PMID:
27080700
44.

Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.

Sanchez A, Schoenfeld JD, Nguyen PL, Fiorentino M, Chowdhury D, Stampfer MJ, Sesso HD, Giovannucci E, Mucci LA, Shui IM.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):197-201. doi: 10.1038/pcan.2016.4. Epub 2016 Mar 1.

45.

Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple.

Raldow AC, Brown JG, Chau N, Davids MS, Margalit DN, Tishler RB, Ng A, Schoenfeld JD.

BJR Case Rep. 2016 Jan 19;2(1):20150271. doi: 10.1259/bjrcr.20150271. eCollection 2016.

46.

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.

Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS.

Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.

47.

Radiation dose and checkpoint blockade immunotherapy: unanswered questions.

Monjazeb AM, Schoenfeld JD.

Lancet Oncol. 2016 Jan;17(1):e3-4. doi: 10.1016/S1470-2045(15)00541-0. Epub 2015 Dec 23. No abstract available.

PMID:
26758758
48.

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review.

Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM, McDermott DF, Kaplan ID.

J Immunother Cancer. 2015 Dec 15;3:50. doi: 10.1186/s40425-015-0095-8. eCollection 2015.

49.

Radiation Oncology--New Approaches in Squamous Cell Cancer of the Head and Neck.

Margalit DN, Schoenfeld JD, Tishler RB.

Hematol Oncol Clin North Am. 2015 Dec;29(6):1093-106. doi: 10.1016/j.hoc.2015.07.008. Review.

PMID:
26568550
50.

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab.

Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD.

Oncoimmunology. 2015 May 28;4(11):e1046028. eCollection 2015 Nov.

Supplemental Content

Loading ...
Support Center